CORONA Remedies Limited has informed the Exchange about Investor Presentation
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
CORONA Remedies Limited filed its January 2026 investor presentation with the exchanges, sharing business overview and financial performance post its December 2025 listing. Q2 FY26 revenue grew 15.1% year-on-year to Rs 361.1 crore, with EBITDA up 17.4% at Rs 78.5 crore (margin expanded 40 bps to 21.7%) and PAT rising 21.8% to Rs 52.3 crore. H1 FY26 revenue grew 17% to Rs 707.7 crore, EBITDA jumped 27.4% to Rs 148.3 crore with margin up 170 bps to 20.9%, and PAT surged 35.1% to Rs 98.5 crore. The company has delivered a 16.8% revenue CAGR over three years, growing 1.82x faster than the Indian pharmaceutical market, and ranks #6 in Women's Healthcare and #5 in Pain Management. Future strategy targets expansion into nephrology, CNS, oncology and dermatology, continued acquisitions, and overseas market entry, with a target of 57-59% chronic portfolio contribution by FY30.
The presentation showcases strong topline growth and consistent margin expansion in a recently listed pharma name, likely to support positive investor sentiment. The clear multi-year roadmap and improving margin trajectory make this a constructive update for shareholders, though execution of acquisitions and therapeutic expansion will be key to sustaining growth.